Share This Article:

Determination of Fenofibrate and the Degradation Product Using Simultaneous UV-Derivative Spectrometric Method and HPLC

Abstract Full-Text HTML Download Download as PDF (Size:1843KB) PP. 332-343
DOI: 10.4236/ajac.2011.23041    7,587 Downloads   16,587 Views   Citations

ABSTRACT

Two new selective, precise, and accurate methods were developed for the determination of fenofibrate in the presence of its basic degradation product. In the first method fenofibrate was determined using an algorithm bivariate calibration derivative method, in which an optimum pair of wavelengths was chosen for the determination of different binary mixtures. In the second method (HPLC), separation was achieved on RESTEK Pinnacle II phenyl column (5 µm, 250 × 4.6 mm) and Pinnacle II phenyl (5 µm, 10 × 4 mm) guard cartridge using a mobile phase consisting of methanol –0.1% phosphoric acid (60:40, v/v) at a flow rate 2 mL●min–1, and the column oven temperature was set at 50°C. The UV detector was time programmed at 302 nm and 289 nm for the internal standard (I.S.) and fenofibrate, respectively. The proposed methods were successfully applied for the determination of fenofibrate and its degradation product in the laboratory-prepared mixture and in pharmaceutical formulation. The assay results obtained using the bivariate method were statistically compared to those of the HPLC method and good agreement was observed.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

F. Salamaa, M. Nassar, M. El-Din, K. Attia and M. Kaddah, "Determination of Fenofibrate and the Degradation Product Using Simultaneous UV-Derivative Spectrometric Method and HPLC," American Journal of Analytical Chemistry, Vol. 2 No. 3, 2011, pp. 332-343. doi: 10.4236/ajac.2011.23041.

References

[1] British Pharmacopoeia Commission Secretariat of the Medicines and Healthcare products Regulatory Agency, “British Pharmacopoeia,” Stationary Office, London, 2004, p. 639.
[2] M. A. Koda-Kimble, L. Y. Young, W. A. Kradjan, B. J. Guglielmo, B. K. Alldredge and R. L. Corelli, “Applied Therapeutics the Clinical Use of Drugs CD-ROM,” 8th Edition, Lippincott Williams &Wilkins, Philadelphia, 2005, pp. 50-77.
[3] T. V. Madureira, M. J. Rocha, Q. B. Cass and M. E. Tiritan, “Development and Optimization of a HPLC-DAD Method for the Determination of Diverse Pharmaceuticals in Estuarine Surface Waters,” Journal of Chromatographic Science, Vol. 48, No. 3, 2010, pp. 176-182.
[4] R. J. Straka, R. T. Burkhardt and J. E. Fisher, “Determination of Fenofibric Acid Concentrations by HPLC after Anion Exchange Solid-Phase Extraction from Human Serum,” Therapeutic Drug Monitoring, Vol. 29, No. 2, 2007, pp. 197-202. doi:10.1097/ftd.0b013e318030860a
[5] A. W. Meikle, J. Findling, M. M. Kushnir, A. L. Rockwood, G. J. Nelson and A. H. Terry, “Pseudo-Cushing Syndrome Caused by Fenofibrate Interference with Urinary Cortisol Assayed by High-Performance Liquid Chromatography,” Journal of Clinical Endocrinology & Metabolism, Vol. 88, No. 8, 2003, pp. 3521-3524. doi:10.1210/jc.2003-030234
[6] A. L?ssner, P. Banditt and U. Tr?ger, “Rapid and Simple Method for Detection of Fenofibric Acid in Human Serum by High-Performance Liquid Chromatography,” Pharmazie, Vol. 56, No. 1, 2001, pp. 50-51.
[7] B. Streel, P. Hubert and A. Ceccato, “Determination of Fenofibric Acid in Human Plasma Using Automated Solid-Phase Extraction Coupled to Liquid Chromatography,” Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 942, No. 2, 2001, pp. 391-400.
[8] P. M. Lacroix, B. A. Dawson, R. W. Sears, D. B. Black, T. D. Cyr and J. C. Ethier, “Fenofibrate Raw Materials: HPLC Methods for Assay and Purity and an NMR Method for Purity,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 18, No. 3, 1998, pp. 383-402. doi:10.1016/S0731-7085(98)00051-X
[9] S. Abe, K. Ono, M. Mogi and T. Hayashi, “High-Performance Liquid Chromatographic Method for the Determination of Fenofibric Acid and Reduced Fenofibric Acid in Human Blood, Plasma and Urine,” Yakugaku Zasshi, Vol. 118, No. 10, 1998, pp. 447-455.
[10] L. D. Masnatta, L. A. Cuniberti, R. H. Rey and J. P. Werba, “Determination of Bezafibrate, Ciprofibrate and Fenofibric Acid in Human Plasma by High-Performance Liquid Chromatography,” Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 687, No. 2, 1996, pp. 437-442. doi:10.1016/S0378-4347(96)00254-X
[11] K. Doser, R. Guserle, V. Nitsche and G. Arnold, “Comparative Steady State Study with 2 Fenofibrate 250 mg Slow Release Capsules. An Example of Bioequivalence Assessment with a Highly Variable Drug,” International Journal of Clinical Pharmacology, Therapy and Toxicology, Vol. 34, No. 8, 1996, pp. 345-348.
[12] A. A. Kadav and D. N. Vora, “Stability Indicating UPLC Method for Simultaneous Determination of Atorvastatin, Fenofibrate and their Degradation Products in Tablets,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 48, No. 1, 2008, pp. 120-126. doi:10.1016/j.jpba.2008.05.018
[13] A. El-Gindy, S. Emara, M. K. Mesbah and G. M. Hadad, “Pectrophotometric and Liquid Chromatographic Determination of Fenofibrate and Vinpocetine and their Hydrolysis Products,” Farmaco, Vol. 60, No. 5, 2005, pp. 425-438. doi:10.1016/j.farmac.2005.01.013
[14] D. Bhavesh, S. Shah and Shivprakash, “Determination of Genofibric Acid in Human Plasma by Ultra Performance Liquid Chromatography-Electrospray Ionization Mass Spectrometry: Application to a Bioequivalence Study,” Biomedical Chromatography, Vol. 23, No. 9, 2009, pp. 922-928. doi:10.1002/bmc.1203
[15] A. Liu, A. D. Patterson, Z. Yang, X. Zhang, W. Liu, F. Qiu, H. Sun, K. W. Krausz, J. R. Idle, F. J. Gonzalez and R. Dai, “Fenofibrate Metabolism in the Cynomolgus Monkey Using Ultraperformance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry-Based Metabolomics,” Drug Metabolism and Disposition, Vol. 37, No. 6, 2009, pp. 1157-1163. doi:10.1124/dmd.108.025817
[16] M. D. Hernando, M. Petrovic, A. R. Fernández-Alba and D. Barceló, “Analysis by Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry and Acute Toxicity Evaluation for Beta-Blockers and Lipid-Regulating Agents in Wastewater Samples,” Journal of Chromatography A, Vol. 1046, No. 1-2, 2004, pp. 133-140.
[17] P. Vazquez-Roig, R. Segarra, C. Blasco, V. Andreu and Y. Picó, “Determination of Pharmaceuticals in Soils and Sediments by Pressurized Liquid Extraction and Liquid Chromatography Tandem Mass Spectrometry,” Journal of Chromatography A, Vol. 1217, No. 16, 2010, pp. 2471-2483. doi:10.1016/j.chroma.2009.11.033
[18] ?. Komsta, G. Misztal, E. Majchrzak and A. Hauzer, “Separation of Fibrate-Type Antihyperlipidemic Drugs by Capillary Electrophoresis and their Quantitation in Pharmaceuticals,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 41, No. 2, 2010, pp. 408-414. doi:10.1016/j.jpba.2005.11.032
[19] Z. K. Shihabi, “Fenofibrate and Fenofibric Acid Analysis by Capillary Electrophoresis,” Electrophoresis, Vol. 25, No. 10-11, 2004, pp. 1648-1651. doi:10.1016/j.jpba.2005.11.032
[20] M. A. Korany, I. I. Hewala and K. M. Abdel-Hay, “Determination of Etofibrate, Fenofibrate, and Atorvastatin in Pharmaceutical Preparations and Plasma Using Differential Pulse Polarographic and Square Wave Voltammetric Techniques,” Journal of AOAC (Association of Official Agricultural Chemists) International, Vol. 91, No. 5, 2008, pp. 1051-1058.
[21] C. Yardimci and N. Ozaltin, “Electrochemical Studies and Square-Wave Voltammetric Determination of Fenofibrate in Pharmaceutical Formulations,” Analytical and Bioanalytical Chemistry, Vol. 378, No. 2, 2004, pp. 495- 498. doi:10.1007/s00216-003-2246-x
[22] Nagaraj, K. Vipul and M. Rajshree, “Simultaneous Quantitative Resolution of Atorvastatin Calcium and Fenofibrate in Pharmaceutical Preparation by Using Derivative ratio Spectrophotometry and Chemometric Calibrations,” Analytical Sciences, Vol. 23, No. 4, 2007, pp. 445-451. doi:10.2116/analsci.23.445
[23] P. L. Lopez-de-Alba, L. Lopez-Martinez, K. Wrobel- Kaczmarczyk, K. Wrobel-Zasada, J. Amador-Hernandez and M. L. Yepez-Murrieta, “Application of the Bivariate Spectrophotometric Method for the Determination of Metronidazole, Furazolidone and Di-Iodohydroxyquinoline in Pharmaceutical Formulations,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 16, No. 2, 1997, pp. 349-355. doi:10.1016/S0731-7085(97)00068-X
[24] L. Lopez-Martinez, P. L. Lopez-de-Alba and V. Cedra-Martin, “Bivariate Calibration as an Alternative for Zero-Crossing Technique in the Resolution of Binary Mixtures by Dderivative Spectrophotometry,” Analytical Letters, Vol. 34, No. 14, 2004, pp. 2563-2583. doi:10.1016/S0731-7085(97)00068-X
[25] C. K. Markopoulou, E. T. Malliou and J. E. Koundourellis, “Chemometric and Derivative Methods as Flexible Spectrophotometric Approaches for Dissolution and AsSaying Tests in Multicomponent Tablets,” Farmaco, Vol. 59, No. 8, 2004, pp. 627-636. doi:10.1016/j.farmac.2004.02.006
[26] F. H. Metwally, “Simultaneous Determination of Nifuroxazide and Drotaverine Hydrochloride in Pharmaceutical Preparations by Bivariate and Multivariate Spectral Analysis,” Spectrochemica Acta, Vol. 69, No. 2, 2008, pp. 343-349. doi:10.1016/j.saa.2007.04.004
[27] C. K. Markopoulou and J. E. Koundourellis, “Two Derivative Spectrophotometric Methods for the Simultaneous Determination of Lovastatin Combined with Three Antioxidants,” Pharmaceutical and Biomedical Analysis, Vol. 33, No. 5, 2003, pp. 1163-1173. doi:10.1016/S0731-7085(03)00429-1
[28] D. L. Massart, B. G. M. Vandeginste, S. N. Deming, Y. Michotte and L. Kaufman, “Chemometrics,” Elsevier, Amsterdam, 1988, p. 124.
[29] J. Karpin′ska, A. Wiszowata and M. Skoczylas, “Simultaneous Determination of Levomepromazine Hydrochloride and Its Sulfoxide by UV-Derivative Spectrophotometry and Bivariate Calibration Method,” Analytical Letters, Vol. 39, No. 6, 2006, pp. 1129-1141. doi:10.1080/00032710600620609
[30] P. L. Lopez-de-Alba, L. Lopez-Martinez, K. Wrobel-Kaczmarczyk, K. Wrobel-Zasada and J. Amador-Hernandez, “The Resolution of Dye Binary Mixtures by Bivariate Calibration Using Spectrophotometric Data,” Analytical Letters, Vol. 29, No. 3, 1996, pp. 487-503.
[31] P. L. Lopez de Alba, L. Lopez Martinez, L. I. Michelini-Rodriguez, K. Wrobel and J. Amador-Herandez, “Extrac- tion of Sunset Yellow and Tartrazine by Ion-Pair Formation with Adogen-464 and their Simultaneous Determination by Bivariate Calibration and Derivative Spectrophotometry,” Analyst, Vol. 122, No. 12, 1997, pp. 1575-1579. doi:10.1039/a702268i
[32] J. Ermer and J. H. M. Miller, “Method Validation in Pharmaceutical Analysis. A Guide to Best Practice,” WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 2005.

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.